Anders Österborg

Publications
Public outreach and news

Articles

Article: INFECTIOUS DISEASES. 2024;:1-14
Risk of COVID-19 hospitalisation by HIV-status and SARS-CoV-2 vaccination status during pre- and post-Omicron era in a national register-based cohort study in Sweden
Moller IK; Hedberg P; Wagner P; Lindahl H; Nystrom S; Blixt L; Sylvan SE; Nilsdotter-Augustinsson A; Osterborg A; Fredrikson M; Hansson L; Kahn F; Sparen P; Gisslen M; Naucler P; Bergman P; Aleman S; Carlander C
Article: BLOOD. 2024;:blood.2024024667
Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE.
Brown JR; Eichhorst B; Lamanna N; O'Brien SM; Tam CS; Qiu L; Jurczak W; Zhou K; Šimkovič M; Mayer J; Gillespie-Twardy A; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Wang MDY; Salmi T; Wang L; Li J; Wu K; Cohen AC; Shadman M
Article: CELL HOST & MICROBE. 2024;32(2):156-161.e3
Memory T cells effectively recognize the SARS-CoV-2 hypermutated BA.2.86 variant
Muller TR; Gao Y; Wu J; Ribeiro O; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Soderdahl G; Smith CIE; Lore K; Chen MS; Ljungman P; Ingelman-Sundberg HM; Ljunggren H-G; Osterborg A; Sette A; Grifoni A; Aleman S; Buggert M
Article: SCIENCE IMMUNOLOGY. 2023;8(90):eadh0687
SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19
Cai C; Gao Y; Adamo S; Rivera-Ballesteros O; Hansson L; Osterborg A; Bergman P; Sandberg JK; Ljunggren H-G; Bjorkstrom NK; Stralin K; Llewellyn-Lacey S; Price DA; Qin C; Grifoni A; Weiskopf D; Wherry EJ; Sette A; Aleman S; Buggert M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(5):748-756
Incidence of cardiovascular and bleeding events and reasons for discontinuation in patients with chronic lymphocytic leukemia treated with ibrutinib-A retrospective analysis on consecutive patients from a well-defined region
Andersson ML; Johansson H; Osterborg A; Mansson-Broberg A; Hansson L; Palma M
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2023;111(5):715-721
Idelalisib (PI3Kδ inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients
Mattsson A; Sylvan SE; Axelsson P; Ellin F; Kjellander C; Larsson K; Lauri B; Lewerin C; Scharenberg C; Tatting L; Johansson H; Osterborg A; Hansson L
Article: EBIOMEDICINE. 2023;94:104700
Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a one-year follow-up of the prospective clinical trial COVAXID
Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; oesterborg A; Smith CIE; Vesterbacka J; Wullimann D; Cuapio A; Akber M; Bogdanovic G; Muschiol S; aberg M; Lore K; Chen MS; Buggert M; Ljungman P; Aleman S; Ljunggren H-G
Article: JOURNAL OF HEMATOLOGY. 2023;12(4):170-175
Local and Systemic Immunity During Five Vaccinations Against SARS-CoV-2 in Zanubrutinib-Treated Patients With Chronic Lymphocytic Leukemia
Andersson M; Wu J; Wullimann D; Gao Y; Aberg M; Muschiol S; Healy K; Naud S; Bogdanovic G; Palma M; Mellstedt H; Chen P; Ljunggren H-G; Hansson L; Chen MS; Buggert M; Ingelman-Sundberg HM; Osterborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(21):3689-3699
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
Munir T; Moreno C; Owen C; Follows G; Benjamini O; Janssens A; Levin M-D; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Yagci M; Ysebaert L; Qi K; Qi Q; Parisi L; Srinivasan S; Schuier N; Baeten K; Howes A; Caces DB; Niemann CUU; Kater APP
Article: SCIENCE TRANSLATIONAL MEDICINE. 2023;15(704):eadg9452
Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states
Muller TRR; Sekine T; Trubach D; Niessl J; Chen P; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Olofsson A; Hernandez SPA; Gao Y; Cai C; Soderdahl G; Smith CIE; Osterborg A; Lore K; Sallberg Chen M; Ljungman P; Ljunggren H-G; Karlsson ACC; Saini SK; Aleman S; Buggert M
Article: BLOOD ADVANCES. 2023;7(12):2794-2806
BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib
Bonfiglio S; Sutton L-A; Ljungstrom V; Capasso A; Pandzic T; Westrom S; Foroughi-Asl H; Skaftason A; Gellerbring A; Lyander A; Gandini F; Gaidano G; Trentin L; Bonello L; Reda G; Bodor C; Stavroyianni N; Tam CS; Marasca R; Forconi F; Panayiotidis P; Ringshausen I; Jaksic O; Frustaci AM; Iyengar S; Coscia M; Mulligan SP; Ysebaert L; Strugov V; Pavlovsky C; Walewska R; Osterborg A; Cortese D; Ranghetti P; Baliakas P; Stamatopoulos K; Scarfo L; Rosenquist R; Ghia P
Article: PHARMACEUTICS. 2023;15(4):1148
A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells
Ghaderi A; Okhovat M-A; Lehto J; De Petris L; Doulabi EM; Kokhaei P; Zhong W; Rassidakis GZ; Drakos E; Moshfegh A; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: JOURNAL OF CLINICAL ONCOLOGY. 2023;41(5):1035-1045
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial
Hillmen P; Eichhorst B; Brown JR; Lamanna N; O'Brien SM; Tam CS; Qiu L; Kazmierczak M; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Shadman M; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Ji M; Yecies J; Idoine A; Wu K; Huang J; Jurczak W
Article: NEW ENGLAND JOURNAL OF MEDICINE. 2023;388(4):319-332
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Brown JR; Eichhorst B; Hillmen P; Jurczak W; Kazmierczak M; Lamanna N; O'Brien SM; Tam CS; Qiu L; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Wang M-D; Fu L; Li J; Wu K; Cohen A; Shadman M
Journal article: NEW ENGLAND JOURNAL OF MEDICINE. 2023;388(4):319-332
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
Brown JR; Eichhorst B; Hillmen P; Jurczak W; Kazmierczak M; Lamanna N; O'Brien SM; Tam CS; Qiu L; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Wang M-D; Fu L; Li J; Wu K; Cohen A; Shadman M
Article: LEUKEMIA RESEARCH. 2022;122:106945
Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study
Ma S; Rosen ST; Winqvist M; Frankfurt O; Winter JN; Gordon L; Helenowski I; Zhang H; Kreutzer J; Sonnert-Husa S; Osterborg A; Lundin J
Article: PHARMACEUTICS. 2022;14(10):2238
A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells
Ghaderi A; Zhong W; Okhovat MA; Aschan J; Svensson A; Sander B; Schultz J; Olin T; Osterborg A; Hojjat-Farsangi M; Mellstedt H
Article: IMMUNITY. 2022;55(9):1732-1746.e5
Immunodeficiency syndromes differentially impact the functional profile of SARS-CoV-2-specific T cells elicited by mRNA vaccination
Gao Y; Cai C; Wullimann D; Niessl J; Rivera-Ballesteros O; Chen P; Lange J; Cuapio A; Blennow O; Hansson L; Mielke S; Nowak P; Vesterbacka J; Akber M; Perez-Potti A; Sekine T; Muller TR; Boulouis C; Kammann T; Parrot T; Muvva JR; Sobkowiak M; Healy K; Bogdanovic G; Muschiol S; Soderdahl G; Osterborg A; Hellgren F; Grifoni A; Weiskopf D; Sette A; Lore K; Chen MS; Ljungman P; Sandberg JK; Smith CIE; Bergman P; Ljunggren H-G; Aleman S; Buggert M
Article: LANCET ONCOLOGY. 2022;23(8):1031-1043
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
Tam CS; Brown JR; Kahl BS; Ghia P; Giannopoulos K; Jurczak W; Simkovic M; Shadman M; Osterborg A; Laurenti L; Walker P; Opat S; Chan H; Ciepluch H; Greil R; Tani M; Trneny M; Brander DM; Flinn IW; Grosicki S; Verner E; Tedeschi A; Li J; Tian T; Zhou L; Marimpietri C; Paik JC; Cohen A; Huang J; Robak T; Hillmen P
Article: NEJM EVID. 2022;1(7):evidoa2200006
Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities.
Kater AP; Owen C; Moreno C; Follows G; Munir T; Levin M-D; Benjamini O; Janssens A; Osterborg A; Robak T; Simkovic M; Stevens D; Voloshin S; Vorobyev V; Ysebaert L; Qin R; Steele AJ; Schuier N; Baeten K; Caces DB; Niemann CU
Article: NATURE MEDICINE. 2022;28(3):472-476
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
Gao Y; Cai C; Grifoni A; Muller TR; Niessl J; Olofsson A; Humbert M; Hansson L; Osterborg A; Bergman P; Chen P; Olsson A; Sandberg JK; Weiskopf D; Price DA; Ljunggren H-G; Karlsson AC; Sette A; Aleman S; Buggert M
Article: CANCERS. 2022;14(5):1186
Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas
Xagoraris I; Farrajota Neves da Silva P; Kokaraki G; Stathopoulou K; Wahlin B; Osterborg A; Herold N; Ng S-B; Medeiros LJ; Drakos E; Sander B; Rassidakis GZ
Article: MED. 2022;3(2):137-153.e3
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals
Healy K; Pin E; Chen P; Soderdahl G; Nowak P; Mielke S; Hansson L; Bergman P; Smith CIE; Ljungman P; Valentini D; Blennow O; Osterborg A; Gabarrini G; Al-Manei K; Alkharaan H; Sobkowiak MJ; Yousef J; Mravinacova S; Cuapio A; Xu X; Akber M; Lore K; Hellstrom C; Muschiol S; Bogdanovic G; Buggert M; Ljunggren H-G; Hober S; Nilsson P; Aleman S; Chen MS
Article: MOLECULAR MEDICINE. 2022;28(1):20
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals
Cuapio A; Boulouis C; Filipovic I; Wullimann D; Kammann T; Parrot T; Chen P; Akber M; Gao Y; Hammer Q; Strunz B; Potti AP; Ballesteros OR; Lange J; Muvva JR; Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Soderdahl G; Osterborg A; Smith CIE; Bogdanovic G; Muschiol S; Hellgren F; Lore K; Sobkowiak MJ; Gabarrini G; Healy K; Chen MS; Alici E; Bjorkstrom NK; Buggert M; Ljungman P; Sandberg JK; Aleman S; Ljunggren H-G
Article: LEUKEMIA. 2022;36(2):476-481
Covid-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients
Blixt L; Bogdanovic G; Buggert M; Gao Y; Hober S; Healy K; Johansson H; Kjellander C; Mravinacova S; Muschiol S; Nilsson P; Palma M; Pin E; Smith CIE; Stromberg O; Chen MS; Zain R; Hansson L; Osterborg A
Article: EBIOMEDICINE. 2021;74:103705
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial
Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Soderdahl G; Osterborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgstrom E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin A-C; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Lore K; Chen MS; Buggert M; Ljunggren H-G; Ljungman P; Aleman S
Article: BLOOD. 2021;138(18):1768-1773
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
Roeker LE; Eyre TA; Thompson MC; Lamanna N; Coltoff AR; Davids MS; Baker PO; Leslie L; Rogers KA; Allan JN; Cordoba R; Lopez-Garcia A; Antic D; Pagel JM; Martinez-Calle N; Antonio Garcia-Marco J; Hernandez-Rivas J-A; Miras F; Coombs CC; Osterborg A; Hansson L; Seddon AN; Lopez Jimenez J; Wilson MR; El-Sharkawi D; Wojenski D; Ma S; Munir T; Valenciano S; Seymour E; Barr PM; Pu J; Patten PEM; Perini GF; Huntington SF; Parry H; Sundaram S; Skarbnik A; Kamdar M; Jacobs R; Walter H; Walewska R; Broom A; Lebowitz S; Isaac KM; Portell CA; Ahn IE; Ujjani CS; Shadman M; Skanland S; Chong EA; Mato AR
Article: PROSTAGLANDINS & OTHER LIPID MEDIATORS. 2021;156:106575
Intrinsic 5-lipoxygenase activity regulates migration and adherence of mantle cell lymphoma cells
Xia C; Sadeghi L; Straat K; Merrien M; Wright AP; Sander B; Xu D; Osterborg A; Bjorkholm M; Claesson H-E
Article: HAEMATOLOGICA. 2021;106(9):2354-2363
Zanubrutinib monotherapy for patients with treatment-naive chronic lymphocytic leukemia and 17p deletion
Tam CS; Robak T; Ghia P; Kahl BS; Walker P; Janowski W; Simpson D; Shadman M; Ganly PS; Laurenti L; Opat S; Tani M; Ciepluch H; Verner E; Simkovi M; Osterborg A; Trneny M; Tedeschi A; Paik JC; Kuwahara SB; Feng S; Ramakrishnan V; Cohen A; Huang J; Hillmen P; Brown JR
Article: EJHAEM. 2021;2(3):525-529
Temporary cessation of ibrutinib results in reduced grade 3-4 infections and durable remissions-Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia
Lundin J; Mulder TA; Kattstrom M; Wasterlid T; Uddevik A; Mellstedt H; Heimersson K; Hansson L; Palma M; Osterborg A
Article: EJHAEM. 2021;2(3):498-502
A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1⁺ CLL cells
Ghaderi A; Okhovat M-A; Wikanthi LSS; Svensson A; Palma M; Schultz J; Olin T; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY. 2021;269:75-99
Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules.
Hojjat-Farsangi M; Moshfegh A; Schultz J; Norin M; Olin T; Österborg A; Mellstedt H
Article: HAEMATOLOGICA. 2021;106(1):87-97
Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multicenter study
Leeksma AC; Baliakas P; Moysiadis T; Puiggros A; Plevova K; van der Kevie-Kersemaekers A-M; Posthuma H; Rodriguez-Vicente AE; Tran AN; Barbany G; Mansouri L; Gunnarsson R; Parker H; van den Berg E; Bellido M; Davis Z; Wall M; Scarpelli I; Osterborg A; Hansson L; Jarosova M; Ghia P; Poddighe P; Espinet B; Pospisilova S; Tam C; Ysebaert L; Nguyen-Khac F; Oscier D; Haferlach C; Schoumans J; Stevens-Kroef M; Eldering E; Stamatopoulos K; Rosenquist R; Strefford JC; Mellink C; Kater AP
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;191(3):426-432
Risk-adapted bendamustine plus rituximab is a tolerable treatment alternative for elderly patients with chronic lymphocytic leukaemia: a regional real-world report on 141 consecutive Swedish patients
Mattsson A; Sylvan SE; Asklid A; Wiggh J; Winqvist M; Lundin J; Mansouri L; Rosenquist R; Johansson H; Osterborg A; Hansson L
Article: BLOOD. 2020;136(10):1134-1143
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
Mato AR; Roeker LE; Lamanna N; Allan JN; Leslie L; Pagel JM; Patel K; Osterborg A; Wojenski D; Kamdar M; Huntington SF; Davids MS; Brown JR; Antic D; Jacobs R; Ahn IE; Pu J; Isaac KM; Barr PM; Ujjani CS; Geyer MB; Berman E; Zelenetz AD; Malakhov N; Furman RR; Koropsak M; Bailey N; Hanson L; Perini GF; Ma S; Ryan CE; Wiestner A; Portell CA; Shadman M; Chong EA; Brander DM; Sundaram S; Seddon AN; Seymour E; Patel M; Martinez-Calle N; Munir T; Walewska R; Broom A; Walter H; El-Sharkawi D; Parry H; Wilson MR; Patten PEM; Hernandez-Rivas J-A; Miras F; Escalada NF; Ghione P; Nabhan C; Lebowitz S; Bhavsar E; Lopez-Jimenez J; Naya D; Garcia-Marco JA; Skanland SS; Cordoba R; Eyre TA
Article: LEUKEMIA & LYMPHOMA. 2020;61(9):2136-2144
A real-world study of first-line therapy in 280 consecutive Swedish patients ≥80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (≥85 years) do well on curative intended therapy
Asklid A; Sylvan SE; Mattsson A; Winqvist M; Johansson H; Osterborg A; Hansson L
Article: BIOMEDICINES. 2020;8(6):E170-170
ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells
Ghaderi A; Daneshmanesh AH; Moshfegh A; Kokhaei P; Vagberg J; Schultz J; Olin T; Harrysson S; Smedby KE; Drakos E; Rassidakis GZ; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2020;189(4):689-693
Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report
Miklos U; Strugov V; Lewerin C; Grosicki S; Mazur G; Steurer M; Montillo M; Kryachok I; Middeke JM; Rekhtman G; Stefanelli T; Vincent G; Govindaraju S; Osterborg A
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2020;476:112675
Calcein release assay as a method for monitoring serum complement activity during monoclonal antibody therapy in patients with B-cell malignancies
Stasilojc G; Felberg A; Urban A; Kowalska D; Ma S; Blom AM; Lundin J; Osterborg A; Okroj M
Article: HAEMATOLOGICA. 2019;104(4):797-804
FFirst-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013
Sylvan SE; Asklid A; Johansson H; Klintman J; Bjellvi J; Tolvgard S; Kimby E; Norin S; Andersson P-O; Karlsson C; Karlsson K; Lauri B; Mattsson M; Sandstedt AB; Strandberg M; Osterborg A; Hansson L
Article: LEUKEMIA. 2018;32(10):2291-2295
First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells
Hojjat-Farsangi M; Daneshmanesh AH; Khan AS; Shetye J; Mozaffari F; Kharaziha P; Rathje L-S; Kokhaei P; Hansson L; Vagberg J; Bystrom S; Olsson E; Lofberg C; Norstrom C; Schultz J; Norin M; Olin T; Osterborg A; Mellstedt H; Moshfegh A
Article: ANNALS OF ONCOLOGY. 2018;29(Suppl 4):iv96-iv110
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
Aapro M; Beguin Y; Bokemeyer C; Dicato M; Gascon P; Glaspy J; Hofmann A; Link H; Littlewood T; Ludwig H; Osterborg A; Pronzato P; Santini V; Schrijvers D; Stauder R; Jordan K; Herrstedt J
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;183(2):212-224
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes
Palma M; Krstic A; Perez LP; Bergloef A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Hoeglund P; Kimby E; OEsterborg A; Mansson R; Smith CIE
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2018;182(4):504-512
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocyticleukaemia treated with ibrutinib from 3 clinical trials
Jones J; Mato A; Coutre S; Byrd JC; Furman RR; Hillmen P; Osterborg A; Tam C; Stilgenbauer S; Wierda WG; Heerema NA; Eckert K; Clow F; Zhou C; Chu AD; James DF; O'Brien SM
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2018;101(1):68-77
Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients
Palma M; Hansson L; Mulder TA; Adamson L; Nasman-Glaser B; Eriksson I; Heimersson K; Ryblom H; Mozaffari F; Svensson A; Gentilcore G; Osterborg A; Mellstedt H
Article: JOURNAL OF IMMUNOTHERAPY. 2018;41(2):73-83
CD19 Chimeric Antigen Receptor T Cells From Patients With Chronic Lymphocytic Leukemia Display an Elevated IFN- Production Profile
Magalhaes I; Kalland I; Kochenderfer JN; Osterborg A; Uhlin M; Mattsson J
Article: PLOS ONE. 2018;13(6):e0198038
A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib
Daneshmanesh AH; Hojjat-Farsangi M; Ghaderi A; Moshfegh A; Hansson L; Schultz J; Vagberga J; Bystrom S; Olsson E; Olin T; Osterborg A; Mellstedt H
Article: PLOS ONE. 2018;13(2):e0192839
Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells
Kokhaei P; Hojjat-Farsangi M; Mozaffari F; Moshfegh A; Pak F; Rashidy-Pour A; Palma M; Hansson L; Osterborg A; Mellstedt H
Article: ONCOTARGET. 2017;8(61):103731-103743
The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains
Alzrigat M; Parraga AA; Majumder MM; Ma A; Jin J; Osterborg A; Nahi H; Nilsson K; Heckman CA; Oberg F; Kalushkova A; Jernberg-Wiklund H
Article: ANNALS OF HEMATOLOGY. 2017;96(10):1681-1691
Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia
Hansson L; Asklid A; Diels J; Eketorp-Sylvan S; Repits J; Soltoft F; Jaeger U; Osterborg A
Article: HAEMATOLOGICA. 2017;102(3):562-572
T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
Palma M; Gentilcore G; Heimersson K; Mozaffari F; Nasman-Glaser B; Young E; Rosenquist R; Hansson L; Osterborg A; Mellstedt H
Article: ONCOTARGET. 2017;8(6):10213-10224
EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions
Alzrigat M; Parraga AA; Agarwal P; Zureigat H; Osterborg A; Nahi H; Ma A; Jin J; Nilsson K; Oberg F; Kalushkova A; Jernberg-Wiklund H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2017;66(1):91-102
Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints
Winqvist M; Mozaffari F; Palma M; Sylvan SE; Hansson L; Mellstedt H; Osterborg A; Lundin J
Article: HAEMATOLOGICA. 2016;101(12):1573-1580
Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group
Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Osterborg A
Article: ONCOLOGY LETTERS. 2016;12(4):2782-2788
Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions
Hogfeldt T; Jaing C; Mc Loughlin K; Thissen J; Gardner S; Bahnassy AA; Gharizadeh B; Lundahl J; Osterborg A; Porwit A; Zekri A-RN; Khaled HM; Mellstedt H; Moshfegh A
Article: LANCET ONCOLOGY. 2016;17(10):1409-1418
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Osterborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Article: LEUKEMIA & LYMPHOMA. 2016;57(9):2037-2046
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia
Osterborg A; Udvardy M; Zaritskey A; Andersson P-O; Grosicki S; Mazur G; Kaplan P; Steurer M; Schuh A; Montillo M; Kryachok I; Middeke JM; Kulyaba Y; Rekhtman G; Gorczyca M; Daly S; Chang C-N; Lisby S; Gupta I
Article: TUMOR BIOLOGY. 2016;37(9):11947-11957
Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia
Khan AS; Hojjat-Farsangi M; Daneshmanesh AH; Hansson L; Kokhaei P; Osterborg A; Mellstedt H; Moshfegh A
Article: ONCOTARGET. 2016;7(6):6809-6823
Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target
Agarwal P; Alzrigat M; Parraga AA; Enroth S; Singh U; Ungerstedt J; Osterborg A; Brown PJ; Ma A; Jin J; Nilsson K; Oberg F; Kalushkova A; Jernberg-Wiklund H
Article: EXPERIMENTAL HEMATOLOGY. 2016;44(1):38-49.e1
Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study
Sylvan SE; Skribek H; Norin S; Muhari O; Osterborg A; Szekely L
Article: MOLECULAR IMMUNOLOGY. 2015;66(2):164-170
Antibodies reactive to cleaved sites in complement proteins enable highly specific measurement of soluble markers of complement activation
Blom AM; Osterborg A; Mollnes TE; Okroj M
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2015;170(1):40-49
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients
Osterborg A; Wierda WG; Mayer J; Hess G; Hillmen P; Schetelig J; Schuh A; Smolej L; Beck C; Dreyfus B; Hellman A; Kozlowski P; Pfreundschuh M; Rizzi R; Spacek M; Phillips JL; Gupta IV; Williams V; Jewell RC; Nebot N; Lisby S; Dyer MJS
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 2015;45(6):1783-1793
Dendritic cell regulation of NK-cell responses involves lymphotoxin-, IL-12, and TGF-
Sarhan D; Palma M; Mao Y; Adamson L; Kiessling R; Mellstedt H; Osterborg A; Lundqvist A
Article: FUTURE ONCOLOGY. 2015;11(1):51-59
The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Article: PLOS ONE. 2015;10(11):e0142310
Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia.
Hojjat-Farsangi M; Jeddi-Tehrani M; Daneshmanesh AH; Mozaffari F; Moshfegh A; Hansson L; Razavi SM; Sharifian RA; Rabbani H; Österborg A; Mellstedt H; Shokri F
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2014;10(11):3394-3408
Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study
Rossmann E; Osterborg A; Lofvenberg E; Choudhury A; Forssmann U; von Heydebreck A; Schroeder A; Mellstedt H
Article: SUPPORTIVE CARE IN CANCER. 2014;22(8):2197-2206
A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia
Ludwig H; Aapro M; Bokemeyer C; Glaspy J; Hedenus M; Littlewood TJ; Osterborg A; Rzychon B; Mitchell D; Beguin Y
Article: LEUKEMIA & LYMPHOMA. 2014;55(8):1774-1780
Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region
Sylvan SE; Hansson L; Karlsson C; Norin S; Lundin J; Osterborg A
Article: JOURNAL OF CLINICAL PHARMACOLOGY. 2014;54(7):818-827
Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis
Struemper H; Sale M; Patel BR; Ostergaard M; Osterborg A; Wierda WG; Hagenbeek A; Coiffier B; Jewell RC
Article: LEUKEMIA & LYMPHOMA. 2014;55(5):1158-1165
Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas
Hoegfeldt T; Johnsson P; Grander D; Bahnassy AA; Porwit A; Eid S; Osterborg A; Zekri A-RN; Lundahl J; Khaled MH; Mellstedt H; Moshfegh A
Article: MEDICAL ONCOLOGY. 2013;30(4):759
Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement
Okroj M; Eriksson I; Osterborg A; Blom AM
Article: EXPERIMENTAL HEMATOLOGY & ONCOLOGY. 2013;2(1):23
Opticin, a small leucine-rich proteoglycan, is uniquely expressed and translocated to the nucleus of chronic lymphocytic leukemia cells.
Mikaelsson E; Osterborg A; Tahmasebi Fard Z; Mahmoudi A; Mahmoudian J; Jeddi-Tehrani M; Akhondi M; Shokri F; Bishop PN; Rabbani H; Mellstedt H
Article: EXPERIMENTAL HEMATOLOGY. 2013;41(7):615-626
Telomere length and expression of human telomerase reverse transcriptase splice variants in chronic lymphocytic leukemia
Palma M; Parker A; Hojjat-Farsangi M; Forster J; Kokhaei P; Hansson L; Osterborg A; Mellstedt H
Article: LEUKEMIA & LYMPHOMA. 2013;54(5):996-1003
Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures
Hogfeldt T; Bahnassy AA; Kwiecinska A; Osterborg A; Tamm KP; Porwit A; Zekri A-RN; Lundahl J; Khaled HM; Mellstedt H; Moshfegh A
Article: LEUKEMIA & LYMPHOMA. 2013;54(4):843-850
Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies
Daneshmanesh AH; Porwit A; Hojjat-Farsangi M; Jeddi-Tehrani M; Tamm KP; Grander D; Lehmann S; Norin S; Shokri F; Rabbani H; Mellstedt H; Osterborg A
Article: EXPERIMENTAL CELL RESEARCH. 2013;319(5):600-611
An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma
Lin H; Kolosenko I; Bjorklund A-C; Protsyuk D; Osterborg A; Grander D; Tamm KP
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2013;62(1):51-63
T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile
Kiaii S; Kokhaei P; Mozaffari F; Rossmann E; Pak F; Moshfegh A; Palma M; Hansson L; Mashayekhi K; Hojjat-Farsangi M; Osterborg A; Choudhury A; Mellstedt H
Article: PLOS ONE. 2013;8(6):e67601
A Proline/Arginine-Rich End Leucine-Rich Repeat Protein (PRELP) Variant Is Uniquely Expressed in Chronic Lymphocytic Leukemia Cells
Mikaelsson E; Osterborg A; Jeddi-Tehrani M; Kokhaei P; Ostadkarampour M; Hadavi R; Gholamin M; Akhondi M; Shokri F; Rabbani H; Mellstedt H
Article: PLOS ONE. 2013;8(10):e78339
The tyrosine kinase receptor ROR1 is constitutively phosphorylated in chronic lymphocytic leukemia (CLL) cells.
Hojjat-Farsangi M; Khan AS; Daneshmanesh AH; Moshfegh A; Sandin A; Mansouri L; Palma M; Lundin J; Österborg A; Mellstedt H
Article: LEUKEMIA & LYMPHOMA. 2012;53(11):2151-2158
Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis
Hedenus M; Oesterborg A; Tomita D; Bohac C; Coiffier B
Article: CANCER RESEARCH. 2012;72(20):5348-5362
Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro, Ex Vivo, and In Vivo in the 5T33MM Mouse Model
Kharaziha P; De Raeve H; Fristedt C; Li Q; Gruber A; Johnsson P; Kokaraki G; Panzar M; Laane E; Osterborg A; Zhivotovsky B; Jernberg-Wiklund H; Grander D; Celsing F; Bjorkholm M; Vanderkerken K; Panaretakis T
Article: JOURNAL OF CLINICAL ONCOLOGY. 2012;30(25):3093-3099
Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Osterborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Ostenstad B; Fagerli U-M; Gadeberg OV; Sundstrom C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
Article: LEUKEMIA. 2012;26(6):1348-1355
Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells
Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi A-R; Hadavi R; Osterborg A; Shokri F; Rabbani H; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(6):865-879
Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria
Palma M; Hansson L; Choudhury A; Nasman-Glaser B; Eriksson I; Adamson L; Rossmann E; Widen K; Horvath R; Kokhaei P; Vertuani S; Mellstedt H; Osterborg A
Article: CLINICAL CANCER RESEARCH. 2012;18(8):2230-2239
The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin
Lemaire M; Fristedt C; Agarwal P; Menu E; Van Valckenborgh E; De Bruyne E; Osterborg A; Atadja P; Larsson O; Axelson M; Van Camp B; Jernberg-Wiklund H; Vanderkerken K
Article: MEDICAL ONCOLOGY. 2011;28(4):1210-1217
Phase I/II randomised study of a novel erythropoiesis-stimulating agent (AMG 114) for the treatment of anaemia with concomitant chemotherapy in patients with non-myeloid malignancies
de Boer R; Clemens M; Renczes G; Kotasek D; Prausova J; Marschner N; Hedenus M; Doshi S; Hendricks L; Osterborg AC
Article: BLOOD. 2011;118(19):5126-5129
Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study
Wierda WG; Padmanabhan S; Chan GW; Gupta IV; Lisby S; Osterborg A
Article: LANCET ONCOLOGY. 2011;12(11):1013-1022
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Pfreundschuh M; Kuhnt E; Truemper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani P-L; Shpilberg O; Kvaloy S; Brown PDN; Stahel R; Milpied N; Lopez-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N
Article: ANNALS OF ONCOLOGY. 2011;22(3):664-670
Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study
Rieger M; Osterborg A; Pettengell R; White D; Gill D; Walewski J; Kuhnt E; Loeffler M; Pfreundschuh M; Ho AD
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2010;151(4):327-335
Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells
Choudhury A; Derkow K; Daneshmanesh AH; Mikaelsson E; Kiaii S; Kokhaei P; Osterborg A; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2010;150(5):565-573
Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma
d'Amore F; Radford J; Relander T; Jerkeman M; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Hagberg H
Article: PLOS ONE. 2010;5(7):e11483
Polycomb Target Genes Are Silenced in Multiple Myeloma
Kalushkova A; Fryknas M; Lemaire M; Fristedt C; Agarwal P; Eriksson M; Deleu S; Atadja P; Osterborg A; Nilsson K; Vanderkerken K; Oberg F; Jernberg-Wiklund H
Article: JOURNAL OF CLINICAL ONCOLOGY. 2010;28(10):1749-1755
Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
Wierda WG; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJS; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell CA; Oesterborg A
Article: EXPERT OPINION ON BIOLOGICAL THERAPY. 2010;10(3):439-449
Ofatumumab, a human anti-CD20 monoclonal antibody
Osterborg A
Article: CLINICAL ADVANCES IN HEMATOLOGY AND ONCOLOGY. 2010;8(1):28-30
Advances in LLM. Ofatumumab: a new agent for chronic lymphocytic leukemia.
Osterborg A
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2009;69(6):529-536
Generation of a Dendritic Cell-based Vaccine in Chronic Lymphocytic Leukaemia Using CliniMACS Platform for Large-scale Production
Adamson L; Palma M; Choudhury A; Eriksson I; Nasman-Glaser B; Hansson M; Hansson L; Kokhaei P; Osterborg A; Mellstedt H
Article: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2009;58(1):111-120
Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study
Mozaffari F; Lindemalm C; Choudhury A; Granstam-Bjorneklett H; Lekander M; Nilsson B; Ojutkangas M-L; Osterborg A; Bergkvist L; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2009;144(1):78-85
Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia
Karlsson C; Lundin J; Kimby E; Kennedy B; Moreton P; Hillmen P; Osterborg A
Article: INTERNATIONAL JOURNAL OF CANCER. 2008;123(5):1190-1195
Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy
DaneshManesh AH; Mikaelsson E; Jeddi-Tehrani M; Bayat AA; Ghods R; Ostadkarampour M; Akhondi M; Lagercrantz S; Larsson C; Osterborg A; Shokri F; Mellstedt H; Rabbani H
Article: ANNALS OF ONCOLOGY. 2008;19(6):1172-1179
Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC)
Abdalla AO; Kokhaei P; Hansson L; Mellstedt H; Osterborg A
Article: INVESTIGATIONAL NEW DRUGS. 2008;26(2):139-149
Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
Jensen M; Engert A; Weissinger F; Knauf W; Kimby E; Poynton C; Oliff IA; Rummel MJ; Oesterborg A
Article: LEUKEMIA & LYMPHOMA. 2008;49(1):102-112
Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a:: A randomized phase II study from the Nordic Lymphoma Group
Kimby E; Jurlander J; Geisler C; Hagberg H; Holte H; Lehtinen T; Oestenstad B; Hansen M; Oesterborg A; Linden O; Sundstroem C
Article: ACTA ONCOLOGICA. 2008;47(6):1009-1017
The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia:: A Markov model
Borg S; Glenngard AH; Osterborg A; Persson U
Article: SUPPORTIVE CARE IN CANCER. 2008;16(1):57-65
Immune response, depression and fatigue in relation to support intervention in mammary cancer patients
Lindemalm C; Mozaffari F; Choudhury A; Granstam-Bjorneklett H; Lekander M; Nilsson B; Ojutkangas M-L; Osterborg A; Bergkvist L; Mellstedt H
Article: CYTOMETRY PART B-CLINICAL CYTOMETRY. 2007;72B(6):450-457
Performance of calibration standards for antigen quantitation with flow cytometry chronic lymphocytic leukemia
Rossmann ED; Lenkei R; Lundin J; Mellstedt H; Oesterborg A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2007;79(5):371-381
Long-term effects of idiotype vaccination on the specific T-cell response in peripheral blood and bone marrow of multiple myeloma patients
Abdalla AO; Hansson L; Eriksson I; Nasman-Glaser B; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF CANCER. 2007;97(6):769-777
Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia
Olsson A; Norberg M; Okvist A; Derkow K; Choudhury A; Tobin G; Celsing F; Osterborg A; Rosenquist R; Jondal M; Osorio LM
Article: MEDICAL ONCOLOGY. 2007;24(3):267-272
Erythropoietin therapy and cancer related anaemia:: updated Swedish recommendations
Ahlqvist-Rastad J; Albertsson M; Bergh J; Birgegard G; Johansson P; Jonsson B; Kjellen E; Pahlman S; Zackrisson B; Osterborg A
Article: BRITISH JOURNAL OF CANCER. 2007;97(1):105-111
NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy
Mozaffari F; Lindemalm C; Choudhury A; Granstam-Bjorneklett H; Helander I; Lekander M; Mikaelsson E; Nilsson B; Ojutkangas M-L; Osterborg A; Bergkvist L; Mellstedt H
Article: CLINICAL CANCER RESEARCH. 2007;13(12):3536-3544
Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies
Kokhaei P; Abdalla AO; Hansson L; Mikaelsson E; Kubbies M; Haselbeck A; Jernberg-Wiklund H; Mellstedt H; Osterborg A
Article: BLOOD. 2007;109(11):4655-4662
Clinical efficacy of zanolimumab (HuMax-CD4):: two phase 2 studies in refractory cutaneous T-cell lymphoma
Kim YH; Duvic M; Obitz E; Gniadecki R; Iversen L; Osterborg A; Whittaker S; Illidge TM; Schwarz T; Kaufmann R; Cooper K; Knudsen KM; Lisby S; Baadsgaard O; Knox SJ
Article: LEUKEMIA. 2007;21(4):627-632
Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies:: a randomized multicenter study
Hedenus M; Birgegard G; Nasman P; Ahlberg L; Karlsson T; Lauri B; Lundin J; Larfars G; Osterborg A
Article: CLINICAL CANCER RESEARCH. 2007;13(5):1503-1510
Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients
Hansson L; Abdalla AO; Moshfegh A; Choudhury A; Rabbani H; Nilsson B; Osterborg A; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2007;136(5):736-744
Phase II study of three dose levels of continuous erythropoietin receptor activator (CERA) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy
Osterborg A; Steegmann JL; Hellmann A; Couban S; Mayer J; Eid JE
Article: EXPERIMENTAL HEMATOLOGY. 2007;35(2):297-304
Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells
Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
Article: HAEMATOLOGICA. 2007;92(1):110-114
Idiotype protein vaccination in combination with adjuvant cytokines in patients with multiple myeloma -: evaluation of T-cell responses by different read-out systems
Abdalla AO; Hansson L; Eriksson I; Nasman-Glaser B; Rossmann ED; Rabbani H; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF CANCER. 2006;95(11):1467-1473
Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer:: a meta-analysis
Aapro M; Coiffier B; Dunst J; Osterborg A; Burger HU
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;135(4):475-485
Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia
Rezvany MR; Tehrani MJ; Karlsson C; Lundin J; Rabbani H; Osterborg A; Mellstedt H
Article: LEUKEMIA & LYMPHOMA. 2006;47(7):1229-1238
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia:: long-term effects of fludarabine and alemtuzumab treatment
Kiaii S; Choudhury A; Mozaffari F; Rezvany R; Lundin J; Mellstedt H; Osterborg A
Article: LANCET ONCOLOGY. 2006;7(5):379-391
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Pfreundschuh M; Trumper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani P-L; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; Lopez-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M
Article: BLOOD. 2006;107(2):669-678
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G₂/M-phase accumulation and apoptosis in multiple myeloma cells
Strömberg T; Ekman S; Girnita L; Dimberg LY; Larsson O; Axelson M; Lennartsson J; Hellman U; Carlson K; Österborg A; Vanderkerken K; Nilsson K; Jernberg-Wiklund H
Article: CYTOTHERAPY. 2006;8(4):318-326
Generation of DC-based vaccine for therapy of B-CLL patients.: Comparison of two methods for enriching monocytic precursors
Kokhaei P; Adamson L; Palma M; Osterborg A; Pisa P; Choudhury A; Mellstedt H
Article: BLOOD. 2005;106(4):1346-1354
Ectopic and IFN-induced expression of Fas overcomes resistance to Fas-mediated apoptosis in multiple myeloma cells
Dimberg LY; Dimberg AI; Ivarsson K; Strömberg T; Österborg A; Nilsson K; Öberg F; Wiklund HJ
Article: BLOOD. 2005;105(12):4828-4835
Fibromodulin, an extracellular matrix protein:: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma
Mikaelsson E; Danesh-Manesh AH; Lüppert A; Jeddi-Tehrani M; Rezvany MR; Sharifian RA; Safaie R; Roohi A; Österborg A; Shokri F; Mellstedt H; Rabbani H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2005;129(2):206-209
Impact of epoetin-β on survival of patients with lymphoproliferative malignancies:: long-term follow up of a large randomized study
Österborg A; Brandberg Y; Hedenus M
Article: INTERNATIONAL JOURNAL OF CANCER. 2005;113(5):730-737
High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia
Morales AA; Olsson A; Celsing F; Österborg A; Jondal M; Osorio LM
Article: MEDICAL ONCOLOGY. 2005;22(3):291-302
Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL) comparison of indolent and progressive disease
Kiaii S; Choudhury A; Mozaffari F; Kimby E; Österborg A; Mellstedt M
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2004;33(6):423-427
Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone
van Vollenhoven RF; Gunnarsson I; Welin-Henriksson E; Sundelin B; Österborg A; Jacobson SH; Klareskog L
Article: LEUKEMIA. 2004;18(11):1810-1815
Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL
Kokhaei P; Choudhury A; Mahdian R; Lundin J; Moshfegh A; Österborg A; Mellstedt H
Article: EUROPEAN JOURNAL OF CANCER. 2004;40(15):2201-2216
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer
Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Österborg A; Repetto L; Soubeyran P
Article: BLOOD. 2004;104(4):948-955
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
Hale G; Rebello P; Brettman LR; Fegan C; Kennedy B; Kimby E; Leach M; Lundin J; Mellstedt H; Moreton P; Rawstron AC; Waldmann H; Osterborg A; Hillmen P
Article: SEMINARS IN HEMATOLOGY. 2004;41(3):234-245
Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia
Lundin J; Österborg A
Article: BLOOD. 2004;103(8):3138-3147
Rapamycin sensitizes multiple myeloma cells to apoptosis induced by dexamethasone
Strömberg T; Dimberg A; Hammarberg A; Carlson K; Österborg A; Nilsson K; Jernberg-Wiklund H
Article: BLOOD. 2004;103(8):2920-2924
A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas
Enblad G; Hagberg H; Erlanson M; Lundin J; MacDonald AP; Repp R; Schetelig J; Seipelt G; Österborg A
Article: LEUKEMIA. 2004;18(3):484-490
Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia
Lundin J; Porwit-MacDonald A; Rossmann ED; Karlsson C; Edman P; Rezvany MR; Kimby E; Österborg A; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;124(3):315-324
Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage
Mozaffari F; Hansson L; Kiaii S; Ju XL; Rossmann ED; Rabbani H; Mellstedt H; Österborg A
Article: LEUKEMIA. 2004;18(1):41-47
Expression and transcriptional regulation of functionally distinct Bmf isoforms in B-chronic lymphocytic leukemia cells
Morales AA; Olsson A; Celsing F; Österborg A; Jondal M; Osorio LM
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2003;58(6):601-606
Kinetics of cytokine gene expression in human CD4⁺ and CD8⁺ T-lymphocyte subsets using quantitative real-time PCR
Abdalla AO; Kiaii S; Hansson L; Rossmann ED; Jeddi-Tehrani M; Shokri F; Österborg A; Mellstedt H; Rabbani H
Article: BLOOD. 2003;101(12):4930-4936
T-cell epitopes within the complementarity-determining and framework regions of the tumor-derived immunoglobulin heavy chain in multiple myeloma
Hansson L; Rabbani H; Fagerberg J; Österborg A; Mellstedt K
Article: BLOOD. 2003;101(11):4607-4610
Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells
Rasmussen T; Hansson L; Österborg A; Johnsen HE; Mellstedt H
Article: BLOOD. 2003;101(11):4267-4272
Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome
Lundin J; Hagberg H; Repp R; Cavallin-Stahl E; Fredén S; Juliusson G; Rosenblad E; Tjonnfjord G; Wiklund T; Österborg A
Article: LEUKEMIA. 2003;17(5):894-899
Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL
Kokhaei P; Rezvany MR; Virving L; Choudhury A; Rabbani H; Österborg A; Mellstedt H
Article: BLOOD. 2003;101(3):1063-1070
Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia
Rezvany MR; Jeddi-Tehrani M; Wigzell H; Österborg A; Mellstedt H
Article: HEMATOLOGY JOURNAL. 2003;4(4):248-252
Phase II study of cyclophosphamide, interferon-alpha and betamethasone (CIB) as induction therapy for patients 60-75 years of age with multiple myeloma stages II and III.
Lundin J; Osterborg A; Björkholm M; Björkstrand B; Celsing F; Hjalmar V; Linder O; Luthman M; Merup M; Tidefelt U; Mellstedt H; Myeloma Group of Central Sweden
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2002;119(1):79-86
Randomized, dose-finding study of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies
Hedenus M; Hansen S; Taylor K; Arthur C; Emmerich B; Dewey C; Watson D; Rossi G; Österborg A
Article: BLOOD. 2002;100(3):768-773
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Österborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 2002;20(10):2486-2494
Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies
Österborg A; Brandberg Y; Molostova V; Iosava G; Abdulkadyrov K; Hedenus M; Messinger D
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 2002;68(5):299-306
Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL)
Rossmann ED; Lewin N; Jeddi-Tehrani M; Österborg A; Mellstedt H
Article: MEDICAL ONCOLOGY. 2002;19(4):277-280
Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia
Cavalli-Björkman N; Ösby E; Lundin J; Kalin M; Österborg A; Gruber A
Article: MEDICAL ONCOLOGY. 2002;19:S21-S26
Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia
Osterborg A; Mellstedt H; Keating M
Article: LEUKEMIA. 2001;15(12):1868-1877
Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D
Olsson A; Diaz T; Aguilar-Santelises M; Österborg A; Celsing F; Jondal M; Osorio LM
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;115(2):263-271
Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern
Rezvany MR; Jeddi-Tehrani M; Biberfeld P; Söderlund J; Mellstedt H; Österborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;113(4):1020-1034
Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients.
Myeloma Trialists' Collaborative Group
Article: INTERNATIONAL JOURNAL OF CANCER. 2001;95(3):184-188
Interleukin-10 gene promoter polymorphisms in multiple myeloma
Zheng C; Huang DR; Liu L; Wu RH; Glas SB; Österborg A; Björkholm M; Holm G; Yi Q; Sundblad A
Article: CLINICAL IMMUNOLOGY. 2001;99(1):65-74
Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation
Ullenhag G; Bird C; Ragnhammar P; Frödin JE; Strigård K; Österborg A; Thorpe R; Mellstedt H; Wadhwa M
Article: HEMATOLOGY JOURNAL. 2001;2(5):300-306
Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies.
Rossmann ED; Lundin J; Lenkei R; Mellstedt H; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2001;112(1):155-160
Interleukin 4 therapy for patients with chronic lymphocytic leukaemia:: a phase I/II study
Lundin J; Kimby E; Bergmann L; Karakas T; Mellstedt H; Österborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;111(2):608-617
Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia
Rezvany MR; Jeddi-Tehrani M; Rabbani H; Lewin N; Avila-Cariño J; Österborg A; Wigzell H; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;111(1):230-238
Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia
Rezvany MR; Jeddi-Tehrani M; Rabbani H; Rudén U; Hammarström L; Österborg A; Wigzell H; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2000;109(1):39-45
Interleulkin 6, tumour necrosis factor α, interleukin 1β and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma
Zheng CY; Huang DR; Bergenbrant S; Sundblad A; Österborg A; Björkholm M; Holm G; Yi Q
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1999;63(3):163-170
The influence of interferon-α on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma
Hassan M; Nilsson C; Olsson H; Lundin J; Österborg A
Article: BLOOD. 1999;94(3):1063-1069
Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia:: Major perturbations are preferentially seen within the CD4 T-Cell subset
Rezvany MR; Jeddi-Tehrani M; Österborg A; Kimby E; Wigzell H; Mellstedt H
Article: EUROPEAN JOURNAL OF CANCER. 1999;35:S29-S32
Local low-dose of soluble GM-CSF significantly augments an immune response against tumour antigens in man
Mellstedt H; Fagerberg J; Österborg A
Article: INTERNATIONAL JOURNAL OF CANCER. 1999;80(5):671-680
T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma
Fagerberg J; Yi Q; Gigliotti D; Harmenberg U; Rudén U; Persson B; Österborg A; Mellstedt H
Article: PATHOLOGIE ET BIOLOGIE. 1999;47(2):211-215
Active idiotype vaccination in multiple myeloma -: GM-CSF may be an important adjuvant cytokine
Mellstedt H; Österborg A
Article: JOURNAL OF CLINICAL ONCOLOGY. 1998;16(12):3832-3842
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.
Article: JOURNAL OF CLINICAL ONCOLOGY. 1998;16(10):3257-3263
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas:: A phase II multicenter study
Lundin J; Österborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
Article: BLOOD. 1998;92(2):402-404
Blood dendritic cells from myeloma patients are not infected with Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8)
Yi Q; Ekman M; Anton D; Bergenbrant S; Österborg A; Georgii-Hemming P; Holm G; Nilsson K; Biberfeld P
Article: BLOOD. 1998;92(1):68-75
Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin:: Results from a randomized phase II study and long-term follow-up of 71 patients
Hellström-Lindberg E; Ahlgren T; Beguin Y; Carlsson M; Carneskog J; Dahl IM; Dybedal I; Grimfors G; Kanter-Lewensohn L; Linder O; Luthman M; Löfvenberg E; Nilsson-Ehle H; Samuelsson J; Tangen JM; Winqvist I; Öberg G; Österborg A; Öst Å
Article: BLOOD. 1998;91(7):2459-2466
Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses
Österborg A; Yi Q; Henriksson L; Fagerberg J; Bergenbrant S; Jeddi-Tehrani M; Rudén U; Lefvert AK; Holm G; Mellstedt H
Article: EUROPEAN JOURNAL OF IMMUNOLOGY. 1997;27(9):2245-2252
T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: clonal CD8(+) T cell expansions are found preferentially in patients with a low tumor burden
Halapi E; Werner A; Wahlstrom J; Osterborg A; JeddiTehrani M; Yi Q; Janson CH; Wigzell H; Grunewald J; Mellstedt H
Article: BLOOD. 1997;90(5):1960-1967
Myeloma bone marrow plasma cells: Evidence for their capacity as antigen-presenting cells
Yi Q; Dabadghao S; Osterborg A; Bergenbrant S; Holm G
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1997;234(2):296-299
Activities of vitamin Q(10) in animal models and a serious deficiency in patients with cancer
Folkers K; Osterborg A; Nylander M; Morita M; Mellstedt H
Article: JOURNAL OF CLINICAL ONCOLOGY. 1997;15(4):1567-1574
Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
Osterborg A; Dyer MJS; Bunjes D; Pangalis GA; Bastion Y; Catovsky D; Mellstedt H; Rankin E; Tsekouras C; Pangalis GA; Cavalli F; Sessa C; Huhn D; Marcus R; Maughan T; Poynton C; Nissen N; Carney D; Brittinger G; Uppenkamp M; Elonen E; Teerenhovi L; Engert; Willemze R; KluinNelemans J; Thomas J; Epenetos AA; Nethersell A; Dyer M; Catovsky D; Dicato M; Bastion Y; Coiffier B; Ranada JMF; Crowther D; Woll P; Raemakaers J; dePauw B; Degos L; Gissellbrecht; Reiffers J; Mellstedt H; Fassas A; Anagnostopoulos A; Bunjes D; Jaeger U; Stahel RA
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1997;96(2):338-345
Idiotype-specific T lymphocytes in monoclonal gammopathies: Evidence for the presence of CD4(+) and CD8(+) subsets
Yi Q; Eriksson I; He W; Holm G; Mellstedt H; Osterborg A
Article: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;58(1):5-13
Clonal CD8(+) and CD52(-) T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52)
Osterborg A; Werner A; Halapi E; Lundin J; Harmenberg U; Wigzell H; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;94(3):425-432
Cytokine therapy in multiple myeloma.
Peest D; Bladé J; Harousseau JL; Klein B; Osterborg A; San Miguel JF
Article: BLOOD. 1996;87(7):2675-2682
Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - A randomized multicenter study
Osterborg A; Boogaerts MA; Cimino R; Essers U; Holowiecki J; Juliusson G; Jager G; Najman A; Peest D
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;93(1):151-153
Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia
Osterborg A; Fassas AS; Anagnostopoulos A; Dyer MJS; Catovsky D; Mellstedt H
Article: MEDICAL ONCOLOGY. 1996;13(1):1-7
Idiotype-specific T cells in multiple myeloma: Targets for an immunotherapeutic intervention?
Yi Q; Osterborg A
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;92(4):840-846
Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients
Bergenbrant S; Yi Q; Osterborg A; Bjorkholm M; Osby E; Mellstedt H
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1996;92(1):71-76
Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): Association with malignant transformation
Isaksson E; Bjorkholm M; Holm G; Johansson B; Nilsson B; Mellstedt H; Osterborg A
Article: BLOOD. 1995;86(8):3043-3049
IDIOTYPE-REACTIVE T-CELL SUBSETS AND TUMOR LOAD IN MONOCLONAL GAMMOPATHIES
YI Q; OSTERBORG A; BERGENBRANT S; MELLSTEDT H; HOLM G; LEFVERT AK
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;63(2):190-192
RESPONSE TO INTERFERON THERAPY IN PATIENTS WITH MULTIPLE-MYELOMA CORRELATES WITH EXPRESSION OF THE BCL-2 ONCOPROTEIN
SANGFELT O; OSTERBORG A; GRANDER D; ANDERBRING E; OST A; MELLSTEDT H; EINHORN S
Article: BRITISH JOURNAL OF HAEMATOLOGY. 1995;89(1):110-116
IDIOTYPE-SPECIFIC T-CELLS IN MULTIPLE-MYELOMA STAGE-I - AN EVALUATION BY 4 DIFFERENT FUNCTIONAL TESTS
OSTERBORG A; YI Q; BERGENBRANT S; HOLM G; LEFVERT AK; MELLSTEDT H
Show more

All other publications

Editorial comment: FUTURE ONCOLOGY. 2024;20(12):717-726
Plain language summary of zanubrutinib or ibrutinib in chronic lymphocytic leukemia that is resistant to treatment or has come back after treatment
Brown JR; Eichhorst B; Hillmen P; Jurczak W; Kazmierczak M; Lamanna N; O'Brien SM; Tam CS; Qiu L; Zhou K; Simkovic M; Mayer J; Gillespie-Twardy A; Ferrajoli A; Ganly PS; Weinkove R; Grosicki S; Mital A; Robak T; Osterborg A; Yimer HA; Salmi T; Wang M-D; Fu L; Li J; Wu K; Cohen A; Shadman M
Letter: HAEMATOLOGICA. 2024;109(2):646-651
Systemic and mucosal adaptive immunity to SARS-CoV-2 during the Omicron wave in patients with chronic lymphocytic leukemia
Ingelman-Sundberg HM; Blixt L; Wullimann D; Wu J; Gao Y; Healy K; Muschiol S; Bogdanovic G; Aberg M; Kjellander C; Grifoni A; Sette A; Aleman S; Chen P; Blennow O; Hansson L; Ljunggren H-G; Chen MS; Buggert M; Osterborg A
Letter: ACTA ONCOLOGICA. 2023;62(6):560-564
The BioLymph study - implementing precision medicine approaches in lymphoma diagnostics, treatment and follow-up: feasibility and first results
Smedby KE; Waesterlid T; Tham E; Haider Z; Joelsson J; Thorvaldsdottir B; Krstic A; Wahlin BE; Foroughi-Asl H; Karlsson C; Eloranta S; Saft L; Palma M; Kwiecinska A; Hansson L; Osterborg A; Wirta V; Rassidakis G; Sander B; Sonnevi K; Rosenquist R
Letter: BLOOD. 2022;140(22):2403-2407
Hybrid immunity in immunocompromised patients with CLL after SARS-CoV-2 infection followed by booster mRNA vaccination
Blixt L; Gao Y; Wullimann D; Ingelman-Sundberg HM; Muschiol S; Healy K; Bogdanovic G; Pin E; Nilsson P; Kjellander C; Grifoni A; Sette A; Chen MS; Ljunggren H-G; Buggert M; Hansson L; Osterborg A
Review: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2022;95(4):e13153
Do reduced numbers of plasmacytoid dendritic cells contribute to the aggressive clinical course of COVID-19 in chronic lymphocytic leukaemia?
Smith CIE; Zain R; osterborg A; Palma M; Buggert M; Bergman P; Bryceson Y
Letter: HAEMATOLOGICA. 2022;107(4):1000-1003
T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial
Blixt L; Wullimann D; Aleman S; Lundin J; Chen P; Gao Y; Cuapio A; Akber M; Lange J; Rivera-Ballesteros O; Buggert M; Ljunggren H-G; Hansson L; Osterborg A
Review: FRONTIERS IN IMMUNOLOGY. 2021;12:686768
BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
Palma M; Mulder TA; Osterborg A
Review: CANCERS. 2019;11(7):E915-915
Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application
Mulder TA; Wahlin BE; Osterborg A; Palma M
Letter: HAEMATOLOGICA. 2019;104(5):e208-e210
Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort
Winqvist M; Andersson P-O; Asklid A; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Rosenquist R; Spath F; Hansson L; Osterborg A
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2019;185(1):179-183
HAX-1 overexpression in multiple myeloma is associated with poor survival
Feng X; Kwiecinska A; Rossmann E; Bottai M; Ishikawa T; Patarroyo M; Osterborg A; Porwit A; Zheng C; Fadeel B
Meeting abstract: BLOOD. 2018;132:5569
Five-Year Follow-up of Safety and Efficacy of a Phase III Randomized Trial of Ofatumumab Therapy Versus Physicians' Choice in Patients with Bulky Fludarabine Refractory Chronic Lymphocytic Leukemia
Miklos U; Strugov V; Lewerin C; Grosicki S; Mazur G; Steurer M; Montillo M; Kryachok I; Middeke JM; Rekhtman G; Stefanelli T; Vincent G; Sameera G; Osterborg A
Meeting abstract: BLOOD. 2018;132:2868
Genetic Basis, Expression Patterns and Clinical Significance of PD-L1 in Peripheral T-Cell Lymphomas (PTCL)
Da Silva PFN; Atsaves V; Tsesmetzis N; Kokaraki G; Osterborg A; Rassidakis G
Meeting abstract: BLOOD. 2018;132:4130
The Novel Tumor Suppressor SAMHD1 Is Differentially Expressed and Partly Regulated By MYC in Peripheral T-Cell Lymphomas (PTCL)
Da Silva PFN; Tsesmetzis N; Xagoraris I; Wasik AM; Kokaraki G; Tzoras E; Osterborg A; Sander B; Herold N; Rassidakis G
Meeting abstract: BLOOD. 2018;132:4421
Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatement in Relapsed or Refactory Chronic Lymphocytic Leukemia Patients
Palma M; Heimersson K; Mulder TA; Nasman-Glaser B; Osterborg A; Mellstedt H
Corrigendum: ANNALS OF ONCOLOGY. 2018;29(Suppl 4):iv271
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines.
Aapro M; Beguin Y; Bokemeyer C; Dicato M; Gascón P; Glaspy J; Hofmann A; Link H; Littlewood T; Ludwig H; Österborg A; Pronzato P; Santini V; Schrijvers D; Stauder R; Jordan K; Herrstedt J; ESMO Guidelines Committee
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2018;182(4):590-594
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study
Winqvist M; Palma M; Heimersson K; Mellstedt H; OEsterborg A; Lundin J
Meeting abstract: MOLECULAR IMMUNOLOGY. 2017;89:203
Monitoring of hemolytic activity of serum during alemtuzumab/ofatumumab therapy of chronic lymphocytic leukemia
Stasilojc G; Winqvist M; Blorn A; Osterborg A; Okroj M
Letter: LEUKEMIA & LYMPHOMA. 2017;58(5):1219-1223
Outcomes of second-line treatment in chronic lymphocytic leukemia - a population-based study from a well defined geographical region between 2003 and 2013
Asklid A; Winqvist M; Sylvan SE; Mattsson A; Bjorgvinsson E; Soltoft F; Repits J; Diels J; Osterborg A; Hansson L
Review: ANNALS OF ONCOLOGY. 2017;28(2):218-227
Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force
Stauder R; Eichhorst B; Hamaker ME; Kaplanov K; Morrison VA; Osterborg A; Poddubnaya I; Woyach JA; Shanafelt T; Smolej L; Ysebaert L; Goede V
Meeting abstract: BLOOD. 2016;128(22):2038
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study
Mauro FR; Tedeschi A; Piciocchi A; Motta M; Iannella E; Farina L; Scarfo L; Marasca R; Coscia M; Cortelezzi A; Laurenti L; Melpignano A; Zinzani PL; Molica S; Re F; Andriani A; Vincelli DI; Visco C; Gozzetti A; Orlandi EM; Trentin L; Tani M; Califano C; Tagariello G; Ghia P; Caputo MD; Salaroli A; Innocenti I; Frustaci A; Vitale C; Petulla M; de Fabritiis P; Vignetti M; Fazi P; Foa R
Meeting abstract: BLOOD. 2016;128(22):3235
Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients
Palma M; Krstic A; Berglof A; Wang Q; Blomberg E; Meinke S; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; Kimby E; Hoglund P; Mansson R; Osterborg A; Smith E
Meeting abstract: ANNALS OF ONCOLOGY. 2016;27:vi530
First generation of a small chemical molecule ROR1 RTK tyrosine kinase inhibitor
Mellstedt H; Hojjat-Farsangi M; Daneshmanesh AH; Moshfegh A; Bystrom S; Norin M; Olin T; Schultz J; Vagberg J; Osterborg A
Review: JOURNAL OF DRUG TARGETING. 2016;24(5):373-385
Ibrutinib-A double-edge sword in cancer and autoimmune disorders.
Kokhaei P; Jadidi-Niaragh F; Sotoodeh Jahromi A; Osterborg A; Mellstedt H; Hojjat-Farsangi M
Review: CANCER TREATMENT REVIEWS. 2016;45:68-75
New perspectives on complement mediated immunotherapy
Stasilojc G; Osterborg A; Blom AM; Okroj M
Meeting abstract: BLOOD. 2015;126(23):1745
Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program
Hansson L; Winqvist M; Asklid A; Andersson P-O; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Osterborg A
Meeting abstract: BLOOD. 2015;126(23):2912
First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Vagberg J; Styrbjorn B; Schultz J; Olsson E; Lofberg C; Norstrom C; Norin M; Olin T; Osterborg A; Mellstedt H
Review: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2015;82(3):208-217
Targets for Ibrutinib Beyond B Cell Malignancies
Berglof A; Hamasy A; Meinke S; Palma M; Krstic A; Mansson R; Kimby E; Osterborg A; Smith CIE
Letter: HAEMATOLOGICA. 2015;100(8):e311-e314
Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study
Osterborg A; Jewell RC; Padmanabhan-Iyer S; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Furman RR; Robak T; Hillman P; Trneny M; Dyer MJS; Piotrowska M; Kozak T; Gupta IV; Phillips JL; Goldstein N; Struemper H; Losic N; Lisby S; Wierda WG
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2015;169(3):455-458
The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies.
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Khan AS; Mikaelsson E; Österborg A; Mellstedt H
Meeting abstract: BLOOD. 2014;124(21):4684
Ofatumumab (OFA) Vs. Physician's Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242
Osterborg A; Udvardy M; Zaritskey A; Andersson P-O; Grosicki S; Mazur G; Kaplan P; Steurer M; Schuh A; Montillo M; Kryachok I; Middeke JM; Kulyaba Y; Rekhtman G; Gorczyca M; Daly S; Chang C-N; Lisby S; Gupta I
Review: SEMINARS IN CANCER BIOLOGY. 2014;29:21-31
The receptor tyrosine kinase ROR1-An oncofetal antigen for targeted cancer therapy
Hojjat-Farsangi M; Moshfegh A; Daneshmanesh AH; Khan AS; Mikaelsson E; Osterborg A; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):3184
Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease region
Moshfegh A; Hogfeldt T; Jaing C; Lundahl J; Osterborg A; Loughlin KM; Gardner SN; Gharizadeh B; Porwit A; Bahnassy AA; Zekri A-RN; Khaled HM; Mellstedt H
Meeting abstract: CANCER RESEARCH. 2014;74(19):4770
Anti-ROR1 monoclonal antibodies induce apoptosis in pancreatic cancer cells via the PI3-kinase/AKT/mTOR pathway
Daneshmanesh AH; Hojjat-Farsangi M; Moshfegh A; Mikaelsson E; Khan AS; Osterborg A; Mellstedt H
Review: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2014;89(1):1-15
Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis-A critical review
Beguin Y; Aapro M; Ludwig H; Mizzen L; Osterborg A
Meeting abstract: MOLECULAR IMMUNOLOGY. 2013;56(3):292
Complement-dependent cytotoxicity exerted by two therapeutic anti-CD20 mAbs: Rituximab and ofatumumab in human B-cell malignant cell lines and primary cultures
Okroj M; Eriksson I; Osterborg A; Blom A
Review: CANCER TREATMENT REVIEWS. 2013;39(6):632-639
Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies
Okroj M; Osterborg A; Blom AM
Letter: BRITISH JOURNAL OF HAEMATOLOGY. 2012;159(5):608-612
Phase I study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukaemia: maintaining immune functions during therapy-induced immunosuppression
Sylvan SE; Rossmann E; Mozaffari F; Porwit A; Norin S; Karlsson C; Hansson L; Lundin J; Osterborg A
Meeting abstract: BLOOD. 2012;120(21):1612
Primary Mediastinal B Cell Lymphoma Treated with CHOP-Like Chemotherapy with or without Rituximab: 5-Year Results of the Mabthera International Trial Group (MInT) Study
Witzens-Harig M; Ho AD; Kuhnt E; Trneny M; Rieger M; Osterborg A; Pettengell R; Stevens R; Gill DS; Walewski J; Loeffler M; Pfreundschuh M
Meeting abstract: BLOOD. 2012;120(21):1769
Monoclonal Antibody Against ROR1 in Chronic Lymphocytic Leukemia Cells Induced Apoptosis Via PI3-Kinase/AKT/CREB Pathway
Daneshmanesh AH; Hojjat-Farsangi M; Sandin A; Khan AS; Moshfegh A; Jeddi-Tehrani M; Osterborg A; Mellstedt H
Meeting abstract: BLOOD. 2012;120(21):4583
Dishevelled Proteins of Wnt Signaling Pathways Are Highly Expressed in Chronic Lymphocytic Leukemia
Khan AS; Sandin A; Osterborg A; Hojjat-Farsangi M; Mellstedt H; Moshfegh A
Review: ANNALS OF ONCOLOGY. 2012;23(8):1954-1962
Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron
Aapro M; Osterborg A; Gascon P; Ludwig H; Beguin Y
Meeting abstract: CANCER RESEARCH. 2012;72:3027
Dishevelled proteins are highly upregulated in chronic lymphocytic leukemia
Khan AS; Osterborg A; Moshfegh A; Mellstedt H
Other: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2012;61(4):587-591
First International Meeting of the Thematic Centre for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC) 13-14 June 2011, Ljusterö, Sweden.
Choudhury A; Höglund P; Kiessling R; Kärre K; Lundqvist A; Malmberg K; Mellstedt H; Scheynius A; Winqvist O; Osterborg A
Other: MEDICAL ONCOLOGY. 2011;28(4):1626
RETRACTED ARTICLE: Survival of MM cells is dependent on Notch signaling.
Wiernik PH; Österborg A
Letter: JOURNAL OF CLINICAL ONCOLOGY. 2011;29(17):e525-e526
Too-Low Iron Doses and Too Many Dropouts in Negative Iron Trial?
Aapro M; Beguin Y; Birgegard G; Gascon P; Hedenus M; Osterborg A
Letter: BLOOD CANCER JOURNAL. 2011;1(6):e22
Virus reactivations and serology patterns following first-line therapy with alemtuzumab or fludarabine-based combination therapy in patients with chronic lymphocytic leukemia
Karlsson C; Dahl H; Lundin J; Rossmann E; Brytting M; Mellstedt H; Linde A; Osterborg A
Review: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2010;10(5):361-368
Ofatumumab: A New CD20 Monoclonal Antibody Therapy for B-Cell Chronic Lymphocytic Leukemia
O'Brien S; Osterborg A
Corrigendum: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2010;10(2):157
Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab (vol 9, pg E36, 2009)
Wierda W; Kipps T; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJS; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell C; Osterborg A
Meeting abstract: CLINICAL LYMPHOMA AND MYELOMA. 2009;9(6):e36
Ofatumumab, a Novel CD20 Monoclonal Antibody, Is Active in Patients With Fludarabine- and Alemtuzumab-Refractory or Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Irrespective of Prior Rituximab
Wierda W; Kipps T; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJS; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Davis R; Losic N; Wilms J; Russell C; Osterborg A
Meeting abstract: BLOOD. 2009;114(22):3433-1334
Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab
Osterborg A; Ronn BB; Jewell RC; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Robak T; Furman RR; Hillmen P; Trneny M; Dyer MJS; Padmanabhan S; Piotrowska M; Kozak T; Chan G; Arning M; Losic N; Davis R; Wilms J; Russell CA; Wierda WG
Review: LEUKEMIA. 2009;23(11):1980-1988
Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia
Osterborg A; Foa R; Bezares RF; Dearden C; Dyer MJS; Geisler C; Lin TS; Montillo M; van Oers MHJ; Wendtner C-M; Rai KR
Published conference paper: JOURNAL OF CLINICAL ONCOLOGY. 2009;27(17):2838-2847
Pooled Analysis of Individual Patient-Level Data From All Randomized, Double-Blind, Placebo-Controlled Trials of Darbepoetin Alfa in the Treatment of Patients With Chemotherapy-Induced Anemia
Ludwig H; Crawford J; Osterborg A; Vansteenkiste J; Henry DH; Fleishman A; Bridges K; Glaspy JA
Review: CURRENT HEMATOLOGIC MALIGNANCY REPORTS. 2009;4(1):47-53
Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Osterborg A; Karlsson C; Lundin J
Published conference paper: CANCER IMMUNOLOGY IMMUNOTHERAPY. 2008;57(11):1705-1710
Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia
Palma M; Adamson L; Hansson L; Kokhaei P; Rezvany R; Mellstedt H; Oesterborg A; Choudhury A
Letter: AMERICAN JOURNAL OF HEMATOLOGY. 2008;83(11):880
ESAs not the culprit: More studies required
Ludwig H; Anderson K; Dammacco F; Hedenus M; Osterborg A; Durie B
Editorial comment: LANCET ONCOLOGY. 2008;9(5):412-413
Erythropoietins should be used according to guidelines
Aapro MS; Birgegard G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellstrom-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
Corrigendum: LEUKEMIA. 2008;22(2):462
Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies:: a randomized multicenter study (vol 21, pg 627, 2007)
Hedenus M; Birgegard G; Nasman P; Ahlberg L; Karlsson T; Lauri B; Lundin J; Larfars G; Osterborg A
Meeting abstract: BLOOD. 2007;110(11):999A
Zanolimumab (HuMax-CD4™), a fully human monoclonal antibody:: Efficacy and safety in patients with relapsed or treatment-refractory non-cutaneous CD4⁺ T-cell lymphoma
d'Amore F; Radford J; Jerkeman M; Relander T; Tilly H; Osterborg A; Morschhauser F; Gramatzki M; Dreyling M; Bang B; Baadsgaard O; Hagberg H
Meeting abstract: BLOOD. 2007;110(11):242B
Comparison of gene expression between T cells from CLL patients, myeloma patients and healthy individuals
Choudhury A; Osterborg A; Mashavakhi K; Mosfegh A; Kiaii S; Mellsted H
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2007;5(4):147-148
Evaluation of the association between hemoglobin (Hb) events and safety outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA):: an integrated analysis of patient-level data from 6 randomized, placebo-controlled trials (RCTs) of darbepoetin alfa (DA)
Glaspy J; Osterborg A; Ludwig H; Fleishman A; Lillie T; Suto T; Crawford J
Meeting abstract: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2007;5(4):142-143
Patient-level integrated analysis of data from 6 randomized, double-blind, placebo-controlled trials of darbepoetin alfa (DA) in patients (pts) with chemotherapy-induced anemia (CIA)
Ludwig H; Crawford J; Osterborg A; Fleishman A; Lillie T; Sueto T; Glaspy J
Review: EUROPEAN JOURNAL OF CANCER. 2007;43(3):510-519
Preclinical studies of erythropoietin receptor expression in tumour cells:: Impact on clinical use of erythropoietic proteins to correct cancer-related anaemia
Osterborg A; Aapro M; Cornes P; Haselbeck A; Hayward CRW; Jelkmann W
Review: EUROPEAN JOURNAL OF CANCER. 2007;43(2):258-270
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer:: 2006 update
Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P
Letter: LEUKEMIA. 2006;20(12):2204-2007
Alemtuzumab as first-line therapy for B-cell chronic lymphocytic leukemia:: long-term follow-up of clinical effects, infectious complications and risk of Richter transformation
Karlsson C; Norin S; Kimby E; Sander B; MacDonald AP; Nilsson B; Johansson E; Mellstedt H; Lundin J; Osterborg A
Meeting abstract: BLOOD. 2006;108(11):4B
Functional iron deficiency effectively overcome by adjuvant IV iron during epoetin treatment.
Birgegard G; Osterborg A; Hedenus M
Meeting abstract: BLOOD. 2006;108(11):770A
Zanolimumab, a fully human monoclonal antibody:: Preliminary results of an ongoing clinical trial in CD4⁺ peripheral T-cell lymphomas (PTCL)
d'Amore F; Relander T; Jerkeman M; Hagberg H; Osterborg A; Johnson P; Radford JA; Hancock BW; Gramatzki M; Schmitz N; Tilly H; Morschhauser F; Lisby S; Baadsgaard O
Published conference paper: ANNALS OF ONCOLOGY. 2006;17:x144-x154
The biology and treatment of chronic lymphocytic leukemia
Palma M; Kokhaei P; Lundin J; Choudhury A; Mellstedt H; Osterborg A
Review: SEMINARS IN ONCOLOGY. 2006;33(2):S29-S35
Strategies in the management of alemtuzumab-related side effects
Osterborg A; Karlsson C; Lundin J; Kimby E; Mellstedt H
Letter: BLOOD. 2005;105(10):4148-4149
No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome
Lundin J; Kennedy B; Dearden C; Dyer MJS; Österborg A
Meeting abstract: BLOOD. 2004;104(11):184A-185A
Targeting the insulin-like growth factor-i receptor (IGF-IR) in multiple myeloma cells using selective IGF-IR tyrosine kinase inhibitors.
Stromberg T; Ekman S; Girnita L; Lennartsson J; Hellman U; Carlson K; Osterborg A; Vanderkerken K; Axelson M; Larsson O; Jernberg-Wiklund H
Meeting abstract: BLOOD. 2004;104(11):419A
Long-term Id vaccination combined with IL-12 or IL-12 and GM-CSF in early stage multiple myeloma patients
Hansson L; Abdalla AO; Rabbani H; Osterborg A; Mellstedt H
Meeting abstract: BLOOD. 2004;104(11):689A
T-cell function in patients with B-cell chronic lymphocytic leukemia (B-CLL) following alemtuzumab (Campath®) or fludarabine treatment.
Kiaii S; Mozaffari F; Lundin J; Rezvany R; Chudhury A; Mellstedt H; Osterborg A
Meeting abstract: BLOOD. 2004;104(11):288B
Comparison of antigen-loading strategies for DC-based immunotherapy of B-CLL.
Mellstedt H; Kokhaei P; Osterborg A; Choudhury A
Meeting abstract: BLOOD. 2004;104(11):54A
Downregulating the fibromodulin gene by short interfering RNA causes B-CLL cell death.
Choudhury A; Derkow K; Mikaelsson E; Kokhaei P; Österborg A; Rabbani H; Mellstedt H
Meeting abstract: BLOOD. 2004;104(11):277A
Virus reactivation profile as assessed by PCR and serology pattern following first-line alemtuzumab (anti-CD52 monoclonal antibody, Campath®) therapy in patients with B-CLL.
Karlsson C; Dahl H; Linde A; Lundin J; Björkholm M; Mellstedt H; Osterborg A
Review: CURRENT TREATMENT OPTIONS IN ONCOLOGY. 2004;5(3):203-214
Therapy for mycosis fungoides.
Lundin J; Osterborg A
Published conference paper: SEMINARS IN ONCOLOGY. 2004;31(3):12-18
New erythropoietic proteins: Rationale and clinical data
Osterborg A
Review: CLINICAL ADVANCES IN HEMATOLOGY AND ONCOLOGY. 2004;2(4):233-241
Anemia in multiple myeloma.
Ludwig H; Pohl G; Osterborg A
Review: CLINICAL LYMPHOMA AND MYELOMA. 2004;4(4):220-227
Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia
Keating M; Coutré S; Rai K; Österborg A; Faderl S; Kennedy B; Kipps T; Bodey G; Byrd JC; Rosen S; Dearden C; Dyer MJS; Hillmen P
Letter: LEUKEMIA. 2003;17(11):2252-2254
T-cell signaling and costimulatory molecules in B-chronic lymphocytic leukemia (B-CLL):: an increased abnormal expression by advancing stage
Rossmann ED; Jeddi-Tehrani M; Österborg A; Mellstedt H
Letter: CANCER. 2003;97(12):3125-3126
Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
Österborg A; Brandberg Y
Editorial comment: DRUGS. 2003;63(12):1245-1246
Alemtuzumab -: A viewpoint by Anders!Osterborg
Österborg A
Review: HEMATOLOGY JOURNAL. 2002;3(3):121-130
Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations.
Ludwig H; Rai K; Blade J; Dammacco F; Degos L; Itri L; Kyle R; Liso V; Littlewood TJ; Mandelli F; Meloni G; Molica S; Osterborg A; Pangalis GA; San Miguel J; Schmitt B; Voliotis D
Review: MEDICAL ONCOLOGY. 2000;17:S17-S22
The role of recombinant human erythropoietin in the management of anaemic cancer patients:: focus on haematological malignancies
Österborg A
Published conference paper: ACTA ONCOLOGICA. 2000;39(7):797-800
Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma
Österborg A; Henriksson L; Mellstedt H
Review: CURRENT OPINION IN HEMATOLOGY. 1999;6(3):169-175
Augmentation of the immune response with granulocyte-macrophage colony-stimulating factor and other hematopoietic growth factors.
Mellstedt H; Fagerberg J; Frödin JE; Henriksson L; Hjelm-Skoog AL; Liljefors M; Ragnhammar P; Shetye J; Osterborg A
Editorial comment: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1999;16(1):1
Untitled
Österborg A; Wiernik PH
Review: SEMINARS IN IMMUNOPATHOLOGY. 1999;21(1):19-35
T cell receptor usage in malignant diseases
Halapi E; Jeddi-Tehrani M; Österborg A; Mellstedt H
Review: MEDICAL ONCOLOGY. 1998;15 Suppl 1:S47-S49
Recombinant human erythropoietin (rHuEPO) therapy in patients with cancer-related anaemia: what have we learned?
Osterborg A
Review: LAKARTIDNINGEN. 1998;95(13):1405-1410
[Vaccination against cancer soon a therapeutic possibility. B-cell tumors, colonic cancer and melanoma may be suitable for this treatment].
Mellstedt H; Fagerberg J; Osterborg A
Editorial comment: MEDICAL ONCOLOGY AND TUMOR PHARMACOTHERAPY. 1996;13(3):R3
New applications of GM-CSF
Osterborg A
Show more

Articles

All other publications

News from KI

Events from KI